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The last several decades have seen the emergence of intellectual property rights 
(IPRs), especially patents, as a key issue in developments across the fields of law, the 
economy and the biosciences, and as part of the burgeoning “bioeconomy”. This 
paper examines how the categories of nature and knowledge, so vital to IPR regimes 
that support bioeconomy-type projects, are challenged by the allegation of biopiracy. 
It reflects on the relationship between nature, IPR and the bioeconomy, and presents 
an example of how the creation of new categories, in this case genetic resources, 
come to impact on how we come to understand nature in relation to the economy and 
IPRs. The paper then follows this with an analysis of how knowledge is treated in 
those same systems, focusing specifically on some of the challenges that arise when 
attempting to bring traditional knowledge (TK) under the rubric of the IPR system. 
Finally, it examines the allegation of biopiracy in greater depth, and reflects on how it 
critiques the way the bioeconomy and the IPR regime treat nature, culture, 




Over the last several decades intellectual property rights (IPRs), especially patents2 
have emerged as a key issue for developments across the fields of law, the economy 
and the biosciences. However, as this special issue attests to, there are many who feel 
that the IPR system has not shown itself dynamic enough to deal with some of the 
complicated questions brought up by the interplay between the IPR system and the 
natural world, both human and non-human. It has thus emerged as a key area of 
contestation for many groups concerned about the role IPR will play in the new 
regimes of governance which impact on these areas. This paper will present an 
analysis of one specific area of contestation, namely that of “biopiracy”, and will 
reflect on how the discourse of biopiracy can help us to understand some of the 
current and no doubt future areas of concern for the IPR system at the national and 
indeed at the international levels. 
 
Biopiracy is a term which was first used in 1993 in a Communiqué3 by the Rural 
Advancement Foundation International (RAFI), which has since changed its name to 
the Action Group on Erosion, Technology and Concentration (ETC Group – 
pronounced et cetera group). ETC Group has remained active in the biopiracy 
discourse, among other areas, and its most current definition of biopiracy is: 
 
the appropriation of the knowledge and genetic resources of farming 
and indigenous communities by individuals or institutions who seek 
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exclusive monopoly control (patents or intellectual property) over 
these resources and knowledge.4 
 
The concept of biopiracy gained momentum through the 1990s, largely due to the 
exposure, both in the media and elsewhere, of several high-profile instances where 
allegations of biopiracy were made publicly. Another very prominent activist 
involved in the early deployment of the term was Vandana Shiva, who published a 
book entitled Biopiracy: The plunder of nature and knowledge in 1997.5 In another of 
her books, she offers this definition of biopiracy: 
 
[Biopiracy] refers to the use of intellectual property systems to 
legitimize the exclusive ownership and control over biological 
resources and biological products that have been used over centuries in 
non-industrialized cultures.6 
 
Taken together, these two similar definitions introduce some of the main features of 
the biopiracy discourse which will be revisited later: IPRs, genetic resources and 
“traditional knowledge”. This paper is not concerning itself with complicated 
questions that form the substance of individual claims of biopiracy, as these have been 
extensively investigated elsewhere,7 and are beyond the scope of the present paper. 
However, I will draw on a wide range of these examples, and the writings of these 
actors (ETC Group, Shiva and others) in order to demonstrate the way that the 
discourse of biopiracy, built up through these and other instances where the allegation 
has been used, has come to present a specific challenge to the IPR system. 
 
Since much of the debate about biopiracy has taken place against a backdrop of what 
could be considered a burgeoning “bioeconomy”, the notion of the bioeconomy 
provides a practical demarcation point to examine some of the new developments in 
the realm of IPRs and the natural world. The Organization for Economic Cooperation 
and Development (OECD) gives the most thorough account of the bioeconomy in 
their project, The Bioeconomy to 2030, with the aim to “design a bioeconomy policy 
agenda for governments”.8 For their purposes, they suppose the bioeconomy to be 
“the aggregate set of economic operations in a society that uses the latent value 
incumbent in biological products and processes to capture new growth and welfare 
benefits for citizens and nations”.9 Though the OECD presents this as a new field for 
the economy, I intend to follow Parry in saying that: “[w]hen appropriately 
contextualized within a longer and more nuanced historiography of the social studies 
of technology there seem, in fact, to be remarkably few grounds on which claims for 
the distinctiveness of biotechnology might be made”.10 As such, I will not present a 
thorough analysis of the bioeconomy in the paper, but rather I will use the term 
bioeconomy here as a convenient catch-all to denote the latest in a series of processes, 
occurring over the last several decades, wherein elements of “nature” are increasingly 
brought into the economy and are structured by understanding them in narrowly 
economic terms. 
 
As they have long been considered as an integral part of western capitalist economies, 
it will come as no surprise that IPRs are also integral to the development and the 
shaping of the bioeconomy. On the whole, there are several functions performed by 
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the decisions we make about the direction that IPR regimes take (particularly when 
these decision are about the relationship between the IPR system and living 
organisms), none the least of which is in shaping how we come to understand both 
nature and knowledge itself. As Hilgartner explains: “Like many future-making 
projects, the [bioeconomy project] must be understood not only as an effort to 
anticipate the future but simultaneously as one to shape it […] The project is quite 
self-consciously an effort to advance ‘the bioeconomy’ – both as a concept and as a 
set of technological and economic activities.”11 In this vein, we have to consider 
shifts in IPR regimes as being also social interventions, engaged in the demarcatio
of boundaries and the creation of categories. In this case, the IPR regime is acting t




In many ways, one of the categories most impacted by the bioeconomy is nature itself, 
and it is quite clear that the IPR aspects of the bioeconomy both structure and are 
predicated on a particular version of nature and of patentability, where elements of 
nature can be considered inventions if they can be shown to have been sufficiently 
altered. In applying for a patent, inventors in this system are called upon to 
demonstrate how they have contributed enough of their own labour to a product of 
nature so that it can be considered no longer “natural”. These same inventors must 
also show how their invention is novel, and thus no longer part of an existing body of 
knowledge known to society. This paper will examine each of these aspects of the 
IPR system in turn, and will argue that the categories of nature and knowledge, so 
vital to IPR regimes that support bioeconomy-type projects, are challenged by the 
allegation of biopiracy. In order to do so, this paper will proceed in four parts. The 
first will examine how social scientists have addressed these and related kinds of 
questions as they have emerged over the last several decades. The second will reflect 
on the relationship between nature, IPR and the bioeconomy, and will present an 
example of how the creation of new categories, in this case genetic resources, come to 
impact on how we come to understand nature in relation to the economy. This will be 
followed with an analysis of how knowledge is treated in that same system, focusing 
specifically on some of the challenges that arise when attempting to bring traditional 
knowledge (TK) under the rubric of the IPR system. Finally, I will examine the 
allegation of biopiracy in greater depth, and will reflect on how it critiques the way 
the bioeconomy and the IPR regime treat nature, knowledge, and the relationship 
between them. Throughout, as mentioned above, I will draw on selected examples 
from cases where allegations of biopiracy have been publicized throughout the past 
several years, and which have been fundamental to shaping how the term is 
understood, but also how it challenges the development and expanse of the IPR 
system. 
 
Theorizing the bioeconomy and IPR 
 
Of course, the OECD’s bioeconomic notion that there is a direct connection to be 
made between the economy and the “latent value incumbent in biological products 
and processes” is not at all alien to social scientists, who have long been analyzing 
these developments. As such, it will be instructive at this point to consider how some 
social scientists have reflected on the process(es) whereby economic value is derived 
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from biological products and processes, before moving on to consider IPR and 
biopiracy in greater depth. 
 
Much of the current thinking in the social sciences has focused on the human and 
biomedical aspects of the bioeconomy. Although there is no doubt that the somatic 
elements are principal drivers of the bioeconomy, it is not necessarily appropriate to 
limit the term to its use in this context. In fact, as Rose puts it, “[i]n a sense, 
contemporary projects to embody human desires and aspirations within living entities 
– organisms, organs, cells, molecules – in order to extract a surplus – be it food, 
health or capital – can be traced to much earlier attempts to put the vital properties of 
the natural world to work for humans, as with the domestication of animals and 
plants”.12 Of course, bringing the vital properties of the natural world to work for 
humans did not stop at the mere domestication of animals and plants, as many of the 
original “bioeconomic” forays into the natural world involved some of the earliest 
plant variety protection instruments that enabled in large part the business of seeds to 
become the multi-billion pound industry it has become today.13 It is worth noting at 
this point that, although this paper focuses primarily on some of the more discursive 
aspects of the developments grouped under the rubric of the “bioeconomy” which 
form the subjects for the biopiracy critique, the bioeconomy is not purely a discursive 
exercise. In fact, it is underpinned by very significant and very real resource values in 
the products of the bioeconomy, particularly in areas such as commercial plant 
breeding and pharmaceutical development.14 
 
Waldby provides a possible framework for conceptualizing some of the transitions 
effected by the bioeconomy when she articulates her notion of “biovalue”. As she 
explains, “biovalue refers to the yield of vitality produced by the biotechnological 
reformulation of living processes”.15 She goes on to describe one of the incentives to 
produce “biovalue”, the production of exchange value, and explains, “the production 
of ‘biovalue’ is caught up with the production of capital value. The process of 
producing ‘biovalue’ is also the process of technical innovation that enables the 
patenting of cell lines, genes and transgenic organisms as inventions, securing their 
status as intellectual property and possible sources of profit for their inventors”.16 
 
These resources are also significant to the bioeconomy because their resource 
potential mirrors more general features of speculative finance capital in positioning 
their potentiality as the resource to be exploited. The fact that much of the value that 
may be contained among the diversity of flora and fauna is unknown, or more 
appropriately seen as incumbent, is what gives it, to use Thompson’s term, its 
“promissory value”.17 In a related way, IPR also becomes important to this sector of 
the bioeconomy as it is increasingly not the quantity of the given natural resource that 
is economically significant to this bioeconomic regime, but rather the information that 
it contains. It is no longer a question of growing, gathering, or harvesting the 
biomaterial itself, but of extracting the information within it and commodifying that 
information so that it can be used in industrial processes, pharmaceutical development 
or elsewhere. Thus, in this particular aspect of the bioeconomy, it is the plant’s 
information – genetic or otherwise - that is valuable, rather than the physical plant 
itself; and thus it is through the promissory realm that IPR gets implicated in this 
project at the most intimate of levels.18 
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IPRs also become especially significant to this bioeconomy for the legitimizing or 
normative function that they provide. In particular, they provide the normative frame 
of reference which allows this regime to be understood as the best, or even the only, 
one through which we can govern the relationship between society and “nature”. This 
is an example of what Jasanoff refers to as co-production, which she stresses is where 
“in broad areas of both present and past human activity, we gain explanatory power 
by thinking of natural and social orders as being produced together. […] co-
production is shorthand for the proposition that the ways in which we know and 
represent the world (both nature and society) are inseparable from the ways in which 
we choose to live in it”.19 This co-production is important because it provides a 
convenient way to understand a rather complicated set of processes, and thus 
contributes to IPR being taken for granted as a way to engage with nature. This 
rationale can be used to explain how elements of nature come to be seen as (naturally) 
a promissory resource. As Jasanoff explains: 
 
As a social technology, patents naturalize the idea of property, 
appearing to recognize property rights that are, quite simply, already 
present. Taken as merely ratifying an underlying status quo, patents 
are regarded as apolitical with respect to both the ‘what’ questions 
(what can be owned?) and the ‘who’ questions (who can own it) that 
they regulate; patents operate, in this respect, not as norms but as 
tools. A counter analysis…would point out, however, that patents are 
not simply declaratory instruments that affirm a prior order of 
ownership, but that they create and maintain property rights in specific 
forms that are anything but preordained.20 
 
One of the most important ways in which regimes such as this are justified is through 
making reference to market analogies, often in very normative ways. Sunder Rajan’s 
work on stem cells provides an interesting take on this normalizing of the market 
model for science: 
 
that ‘market logic’ is not natural, but rather a strategic-rhetorical 
invocation that allows the (re)structuring and negotiation of 
biocapitalist terrains. In other words, the apparent naturalization of 
complete commodification as the condition for scientific innovation 
masks the fact that commodification is selected and contested, subject 
to conflicting interests and ethical representations.21 
 
IPR systems are also vital to bioeconomy-type projects because they are instrumental 
in defining what is inventable, and thus what is patentable. This aspect of the IPR 
system obviously leads to very particular understandings of what can count as 
inventible (or perhaps more interestingly what can be considered as already invented), 
but also who can count as an inventor. This system allows for lines of separation to be 
drawn around inventions and knowledge, often in ways that remain blind to the 
potential that they may follow on from a certain collective heritage. As Coombe 
writes: 
 
The range of Western beliefs that define intellectual and cultural 
property laws – that ideas can easily be separated from expressions, 
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that expressions are the singular products of the individual minds of 
Romantic authors, that these expressive works can be abstracted from 
the meaningful words in which they figure to circulate as the signs of 
unique personality, that cultures have essences embodied in objects 
that represent unbroken traditions – are not universal values that 
express the full range of human possibility, but particular, interested 
fictions emergent from a history of colonialism that has disempowered 
many of the world’s peoples.22 
 
In a number of the instances of biopiracy referenced below, it becomes clear that 
while the IPR system might correctly (by its own internal logic) interpret genetic 
resources as patentable, it is not calibrated to deal with instances where those genetic 
resources, or even the patent system, are understood differently. In these instances, the 
normative elements of what counts as nature and what counts as knowledge are 
challenged and reconfigured. In the interest of providing further context to biopiracy 
and IPR, I will first present a brief history of the emergence of the category of 
“genetic resources”, which provides a particularly helpful example of how an 
understanding of nature can be created or reshaped in and by the economy. 
 
Nature/society in the bioeconomy – the evolution of genetic resources  
 
I earlier described briefly how projects such as those captured under the rubric of the 
bioeconomy are geared towards the creation of new or reshaped categories, and are 
thus engaged in a process of, as Hilgartner pointed out, anticipating but also shaping 
the future. One such example of this is the emergence of the concept of “genetic 
resources”, which effectively recasts what was formerly understood primarily as 
“nature” as a potential “genetic” resource. Though nature has of course long been 
thought of as a resource in economic terms, what exactly is understood as genetic 
resources is not so simply defined and is subject to multiple readings. What follows 
will be an examination of the ways in which recognizing genetic resources as a 
category grants nature a new economic, but also a new political and ethical, status. 
 
The first international recognition of genetic resources as a category came though the 
Food and Agriculture Organization (FAO)’s creation of a Commission on Plant 
Genetic Resources in 1983, whose first major action was the development and 
adoption of the “International Undertaking on Plant Genetic Resources”.23 The 
objective of the Undertaking is: 
 
to ensure that plant genetic resources of economic and/or social 
interest, particularly for agriculture, will be explored, preserved, 
evaluated and made available for plant breeding and scientific 
purposes. This Undertaking is based on the universally accepted 
principle that plant genetic resources are a heritage of mankind and 
consequently should be available without restriction.24  
 
It is generally acknowledged that the impetus for this particular undertaking came 
about to address a concern raised by the countries in the developing world about the 
system employed to define these kinds of resources. Specifically, it has to do with a 
tension in how the notion of common heritage was being used at the time. The 
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concern on the part of these developing countries came about in recognizing the 
significance of an increasingly lucrative agri-business industry, and recognizing that 
the value that was being derived from this industry was one that was inherent in the 
plants’ genetics themselves. This genetic material was collected in a variety of ways 
and at a variety of sites over a substantial period of time, but much of it was gathered 
into germplasm banks such as those associated with the Consultative Group on 
International Agricultural Research or International Rice Research Institute. Seed 
companies obtained genetic material from these banks under the understanding that 
the resources contained within them were the common heritage of mankind [sic], and 
used these genetic materials to develop proprietary seed strains that were sold 
worldwide. The tension in this system arose with a recognition that, as Kloppenburg 
puts it, “[w]hereas germplasm flows out of the South as the ‘common heritage of 
mankind’, it returns as a commodity”.25 
 
Much of the interest about this particular issue – the apparent imbalance in who was 
making a profit from genetic material in seeds – came about because of a book 
published by Pat Mooney (director of RAFI/ETC Group) in 1979, called Seeds of the 
Earth. The book proved to be quite controversial on the whole, but even those most 
critical of it, such as Frankel, who referred to it as “propagandist and political but not 
a scientific statement […] full of half-truths and untruths, spurious references and 
misleading quotations taken out of context”,26 acknowledge Witt’s assertion that “it is 
Pat Mooney’s book Seeds of the Earth […] where many developing country delegates 
at the FAO learned of the whole topic of genetic resources”.27 This is significant 
because it manifests a transition from seeing genetic resources and their attendant 
concerns as falling strictly within the realm of science or nature (which, according to 
Frankel, apparently operates entirely apolitically in the interest of preserving a broad 
genetic base for agriculture) to a realm of politics which concerned itself with a new 
set of issues now bundled with genetic resources, such as compensation and equity, 
which were articulated alongside conservation. The importance of this shift cannot be 
underestimated: the new recognition of genetic resources in this way essentially made 
the science of “genetic resources” all the more overtly political, or, in a way, brought 
nature more visibly into the world of politics. 
 
We also see two starkly different versions of common heritage being presented here. 
Although all seem to be willing to support the idea that plant genetic resources are a 
common heritage of mankind, there is a fundamental difference of opinion about 
where these resources, and ultimately this heritage, begin and end. The fact that the 
basis for these commercial seed strains came originally from genetic material of the 
South is something that many of the Southern countries felt justified their claims that 
this furthered a colonial-type exploitation. The seed companies, and the developed 
countries in which they were based, claimed that though the source genetic material 
from these strains may indeed have come from seed banks which stored germplasm 
collected from all over the world, their intervention into the breeding was something 
which could not have happened naturally, and thus obtaining IPR protection for the 
seed strains was justified as it rewarded their innovation. In some ways, this can be 
seen as a fundamental question demarking where nature stops and “invention” begins 
with respect to genetic resources. Taking the most literal reading, as many do, these 
plant genetic resources are too “natural” to be subject to IPR – plants are, after all, 
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products of nature and thus should not be patentable. Privately developed strains of 
plants, however, are put together with natural material which is apparently too 
socially worked upon to be considered natural, and are thus invented and hence 
subject to patentability. In advancing this particular reading of common heritage for 
genetic resources, those interests (mostly from the developed world) are engaged in 
drawing boundaries about what counts as natural and thus common heritage (which is 
consequently unpatentable) in international environmental governance regimes. 
 
Although it did not invent the category of genetic resources per se, the Convention on 
Biological Diversity (CBD), one of the major environmental initiatives to come out of 
the celebrated 1992 Rio Earth Summit, has made some very substantial contributions 
to how it has come to be interpreted, and it has become the principal forum in which 
the genetic resources debate has played out. The Convention’s objectives are defined 
as being the “conservation of biological diversity, the sustainable use of its 
components and the fair and equitable sharing of the benefits arising out of the 
utilization of genetic resources”. In article 2, the Convention text somewhat 
ambiguously defines genetic resources as “genetic material of actual or potential 
value.” Perhaps most succinctly, the CBD’s guide to the convention, Sustaining life 
on earth, explains that the CBD’s overarching responsibility is to “[set] out 
commitments for maintaining the world’s ecological underpinnings as we go about 
the business of economic development”.28 
 
As might be anticipated given the ambiguousness of some of these definitions, the 
CBD also gave rise to further conflicts about exactly what shape our understanding of 
genetic resources would take, and who would come to decide this. The notion of 
genetic resources as a source of economic validation for nature is, of course, 
intimately bound up with the idea of property, and ultimately that of IPR. IPR here 
serves as the means of translation between genetic resources and their benefits, the 
ones which are ostensibly to be shared as per the CBD’s third objective. As McAfee 
explains regarding the place of “genetic resources” in the CBD: 
 
The equation of ‘biodiversity benefits’ with ‘genetic resources’, 
enshrined in the CBD text, represents a discursive conquest by the 
short-sighted instrumentalism of the environmental-economic 
paradigm. It reduces biological diversity to its purported essence as a 
commodity, presumably separable from its complex relationship with 
other ‘units’ of nature, and valuable only to the extent that it is 
consumed.29 
 
What this brief history points to is how the transition to genetic resources effectively 
makes nature thinkable in new ways. What sets this new concept of resources apart is 
that it relates specifically to the genetic aspect of these resources, something which 
creates a dramatically new category in our understanding of our environment. No 
longer, it would seem, are issues of resources limited by the tangibility or even 
corporeality of resources. Thus, genetic resources become thinkable and contestable 
in new ways; in a word, they become governable. 
 
In creating and maintaining this separation, the specific aspect of the bioeconomy at 
issue here – genetic resources – employs (while also being shaped by) an IPR regime 
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which provides the conceptual framework to re-affirm a particular version of nature. 
This version of nature seemingly exists outside of society’s sphere of influence, and 
remains an external, passive, resource pool from which we can draw our new genetic 
resources rather than one that we participate in and are actively involved in shaping. 
This version of nature does not go far enough in recognizing what many understand to 
be nature’s cultural underpinnings – the only version of participation in nature that is 
allowed in this version automatically reconfigures that nature as a possible ownable 
commodity, something which will be taken up more thoroughly in the following 
section. 
 
Knowledge/Society in IPR and the bioeconomy 
 
When considered in relation to the debate at hand, new categories such as genetic 
resources take on an interesting relationship with the bioeconomy (and the IPR 
aspects thereof) where they create and sustain particular versions of both nature and 
society. The version of nature that is supported by the bioeconomy is one where 
inventors can disentangle “products of nature” from both their natural and their socio-
cultural entwinings. At risk of oversimplifying, it can be said that when moving to 
patent an invention derived from nature, inventors engage in a process of 
demonstrating that they have intervened sufficiently enough in their invention so that 
it can no longer be seen as “in” nature. Likewise, they are also called upon to show 
how their invention is different from the “state of the art” (eg, those ideas that are now 
or have been previously held by other patent owners, or are so widely acknowledged 
so as to be considered part of the public domain), and thus to demonstrate how far out 
of the existing body of knowledge they have taken it. 
 
As discussed above, the IPR system and ideas such as the bioeconomy allow for an 
interpretation of nature, culture and IPR which establishes that things rooted in nature 
are unpatentable, as they could only be discovered there, whereas things existing in 
the social realm (ie, human ideas) have been “invented”, thus cannot be construed as 
natural, and are therefore patentable. As Jasanoff explains: 
 
Patents not only underwrite a scheme of property rights, but they order 
the process of invention in two ways that could be seen as intrinsically 
political. One is to designate classes of things that can be considered 
property. The extension of patents to new domains alters basic notions 
of what is a commodity and who can assert ownership over it. When a 
patent is awarded for a biological product, it has the effect of removing 
the thing being patented from the category of nature to the category of 
artifice.30 
 
As explained here, components of biodiversity are brought in to IPR regimes by 
overcoming the notion that they are simply discovered in nature. Nature can no longer 
be an inventor of or by itself. 
 
Likewise, in the process of securing a patent, inventors must also make explicit how 
separate from the “state of the art” their invention is. They must describe how, 
although it might draw on existing ideas from the public domain, their invention 
incorporates an inventive step, is indeed novel and is thus patentable. Thus, in the 
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case of biotechnology inventions, in addition to demonstrating how far out of nature 
an invention is, an inventor also has to demonstrate how far out of culture (this 
common pool of ideas in the public domain), though still not in nature, it is. This 
demonstration, encapsulated in a patent, is a very nuanced and particular notion of 
property, albeit one which has seen wide normative take-up. In the case of 
biotechnology patents, the movement from the realm of the natural into the realm of 
the cultural is what renders these particular “products of nature” patentable. 
 
One cannot, of course, merely move to patent anything that is “discovered in nature” 
as this is precluded by what is often called the “product of nature” doctrine in the 
United States.31 Similarly, one cannot move to patent something which exists in the 
public domain or which is already patented. This is precluded by the concept of prior 
art, which is fundamentally related to two criteria for patentability – novelty and 
inventive (non-obvious) step. WIPO, in their Intellectual Property Handbook, 
explain: “‘Prior art’ is, in general, all the knowledge that existed prior to the relevant 
filing or priority date of a patent application, whether it existed by way of written or 
oral disclosure.”32 This is not to say, however, that this area does not merit further 
consideration. In fact, these inventions’ double movement, out of culture (ie, the 
public domain) and of nature, is a key element of patent system in the bioeconomy, 
but also a key element to many critiques of the patent system more generally. In 
particular, it is at the point where we consider these concepts of the patent system 
alongside critiques of that same system that some of the underlying logics of IPR 
become more apparent and in some ways more problematic. Indeed, it is precisely 
these versions of nature and of knowledge that are constructed by the bioeconomy 
with which many of those presenting contestations such as biopiracy are taking issue. 
 
It is especially this separation of the two realms, or more fundamentally the idea that 
they are separable and that movement from one to the other is possible, which is being 
contested in much of the biopiracy discourse. For example, a group of Brazilian 
shamans made the following submission to WIPO: 
 
As traditional indigenous peoples who inhabit diverse ecosystems, we 
possess knowledge on the sustainable management and use of this 
biological diversity. The knowledge is collective and is not a 
commodity that may be commercialized as any good in the market. Our 
knowledge on biodiversity is not separate from our identities, our laws, 
our institutions, our system of values and our cosmological view as 
indigenous peoples […] As indigenous representatives, we affirm our 
opposition to all forms of patentability arising out of the use of 
traditional knowledge and we request the creation of mechanisms of 
punishment to prevent the threat of our biodiversity)33 
 
The notion that this knowledge would be inseparable from identities, laws, 
institutions, value systems and cosmologies is, of course, one which is fundamentally 
alien to the IPR system. What is at work here is a contest over the IPR system 
generally but also over what is able to “count” as an appropriate translation 
mechanism for the IPR system. If traditional knowledge, reproduced in any of its 
varied forms, is not sufficient to count as prior art, then groups such as the Brazilian 
shamans quoted above will not accept the IPR system as an effective enough 
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interlocutor for their concerns stemming from the exploitation of TK and genetic 
resources. 
 
Too natural/too cultural 
 
As introduced above, biopiracy discourses challenge the normative version of nature, 
knowledge and society and how these are alternatively brought together but also 
forced apart when passed through IPR systems in the bioeconomy. This has been done 
by presenting two overlapping critiques of the IPR system’s treatment of the natural 
and cultural aspects of particular “inventions”, and this has been a key component to 
the discourse around various instances of biopiracy that have become problematic 
over the last several decades. The first of these critiques suggests that there is too 
much “nature” in the inventions claimed, and as such in the relevant aspects of living 
things themselves, for them to be eligible to be considered as invented rather than 
merely “discovered”. The second suggests that there is also too much “culture” in 
these “inventions” for them to be considered as new or novel, and thus eligible 
creations for patentability. The allegation that this knowledge is “too cultural” is made 
in two ways, first by invoking specific instances of prior human influence in the 
shaping of these organisms (such as in the case of patent claims on traditional 
medicines or on agricultural products such as seed strains), and also by invoking a 
much more holistic perspective on the relationship between humans and nature at the 
most general which put humans squarely back into a nature that they are actively 
participating in. The particular artefacts being challenged by the allegation of 
biopiracy are thus positioned uniquely at the nexus of nature/culture – they are at once 
profoundly “natural” as they are derived from plants, animals, or even people 
themselves, but are also profoundly cultural, because they speak to how these 
particular natural artefacts have come about as part of, are shaped by, and exist in 
relation to culture. The next section will examine the nature and cultural aspects of the 
biopiracy discourse more closely. 
 
Too natural – discovery as invention 
 
In their study of anti-GMO campaigns, Heller and Escobar explain that, “biodiversity 
activists emphasize preserving the natural co-evolution of organisms and cultures, and 
thus, embed human beings and culture inside natural systems.”34 Later in that same 
analysis they expand: 
 
for the [biodiversity] activists, as they theorize local practices, nature 
is not an entity ‘out there’ but is produced through the collective 
practices of humans integrated with it (Descola & Palsson, 1996).[35] 
From this perspective, the reductive view of biodiversity in terms of 
genetic resources to be protected through intellectual property rights is 
incoherent and untenable.36 
 
The position of Heller and Escobar’s activists is also echoed in much of the biopiracy 
discourse, with many of the biopiracy activists taking issue with, to use Haraway’s 
formulation, “who gets to count as nature’s author”.37 Much of the rhetoric invoked in 
this regard relies heavily on a certain principle of self-evidence and a deliberately 
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essentialist reading of patent law. By this logic, if the invention derives from nature in 
any way it must therefore be a product of nature, ergo it is not patentable. For 
instance, the text of the Treaty Initiative to Share the Genetic Commons, which was 
spearheaded by Jeremy Rifkin and his organization, the Foundation on Economic 
Trends states: 
 
That the intrinsic value of the Earth’s gene pool, in all of its biological 
forms and manifestations, precedes its utility and commercial value, 
and therefore must be respected and safeguarded by all political, 
commercial and social institutions,  
 
That the Earth’s gene pool, in all of its biological forms and 
manifestations, exists in nature and, therefore, must not be claimed as 
intellectual property even if purified and synthesized in the laboratory,  
 
That the global gene pool, in all of its biological forms and 
manifestations, is a shared legacy and, therefore, a collective 
responsibility38 
 
More than simply relating the ownership of nature via IPR to a point of legal 
interpretation (ie, the product of nature doctrine), the activists that contest biopiracy 
do so in ways that call this system of property itself into question. As seen in the 
excerpt quoted above, many of these groups often invoke an essentialized version of 
nature which posits that there is something inalienably “natural” about nature that 
renders its ownership unethical, or even impossible. There are a number of 
justifications on which this rests, many of which speak to the social embroiling(s) of 
nature, where nature as such is understood to have coevolved with society’s 
understandings of it. As RAFI explains in a press release related to a particularly 
acrimonious “biopiracy” debate regarding an International Consultative Biodiversity 
Group39 project in the Chiapas region of Mexico: 
 
No "Wild Kingdoms": Bioprospectors must assume - unless there is 
proof otherwise - that all materials they encounter have been nurtured 
and enhanced by communities. [In the Maya-ICBG case a] large 
community garden was mistaken for a "natural" forest. Similarly, soils, 
insects, and fungi first assumed to be unused upon closer scrutiny have 
been found to have longstanding medicinal or other purposes.40 
 
Other actors who attempt to draw attention to biopiracy present nature’s creative and 
reproductive capacity to serve as self-evidence of the futility and hubris of attempting 
to “own” nature. This logic is carried forward by Vandana Shiva, in much of her 
writing on biopiracy. In Biopiracy: The plunder of nature and knowledge, for 
example, she writes that “biotechnology, as the handmaiden of capital in the 
postindustrial era, makes it possible to colonize and control that which is autonomous, 
free, and self-regenerative”.41 Later in the same account, she explains: 
 
Certainly, the idea of owning life is not new; people own their pets and 
farmers own their livestock. Yet IPRs create a new concept of 
ownership. It is not just the implanted gene, or one generation of 
animals, that is being claimed as intellectual property, but the 
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reproduction of the entire organism, including future generations 
covered by the life of the patent.42 
 
Shiva’s point here presents IPRs as the tool through which seeds, in this case, are 
denied their “naturalness” and become patentable, and thus commodifiable at what 
she sees as the most intimate of levels. For her, the IPR system is an ill-equipped and 
inappropriate mechanism for deciding what constitutes something which is “from 
nature”. Further, the distinction which is currently made between the natural and the 
invented does not go nearly far enough in recognizing nature’s own inventive capacity 
and thereby imposes a false notion of human invention onto the natural. In these 
cases, though Shiva knows well that there is a time limit to patents, these particular 
patents cross over into a more symbolic realm, and do so on behalf of the IPR system 
more generally. When considered in terms of nature’s perceived self-evidence as 
“natural” and its autonomy, including its autonomy to reproduce, then the limits that 
would be placed upon these organisms by seeing them as patentable would make 
them “too natural” to be considered invented. 
 
Too cultural – public domain or private ownership? 
 
Along with arguing that these contentious inventions are “too natural” to be patented, 
those alleging biopiracy also see the place of culture/society in this system as 
problematic. These critiques challenge the logic behind a perceived separation of the 
public and the private domains as they pertain to ownership and control over 
inventions that can be seen to have some form of prior cultural basis, such as in the 
case of TK. In brief, the problem in these instances appears to be that there is a claim 
that there is too much knowledge already there, albeit unrecognized by the system, to 
allow these “inventions” to be patented. 
 
Much of the thrust of this “too cultural” aspect of the biopiracy discourse thus takes 
issue with the recognition of prior art in patent claims. In many of the cases where 
biopiracy has been alleged, one of the claims made is that prior art has not been 
adequately taken into account by the patent system. This is often explained away by 
those in favour of robust IPR regimes as simply untrue, or, at worst, as a case of a 
“bad patent” being issued, where prior art was indeed not recognized. Biopiracy 
activists, however, often present this as a more fundamental, systemic problem with 
what is allowed to “count” as prior art within the IPR system. Specifically, it is 
claimed that Euro-American IPR systems are blind to types of prior art that might not 
exist in immediately accessible formats. For example, this was a major point of 
contention in both the neem and turmeric biopiracy challenge cases. The neem case 
refers to a patent granted to WR Grace and Co. for an insecticide/fungicide derived 
from the neem tree, which was subject to a very public patent challenge.43 The 
turmeric case refers to US patent 5, 401, 504, granted initially to two scientists from 
the University of Mississippi for the use of turmeric for healing wounds. As Genetic 
Resources Action International (GRAIN) explains: “The Indian government 
challenged the patent as blatant theft, and provided endless research papers predating 
the patent providing that turmeric has long been used in India to heal wounds. In the 
face of this overwhelming evidence, the US Patent and Trademark office rejected all 6 
patent claims”.44 With specific reference to the turmeric case, Shiva takes issue with 
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those that would attempt to dismiss biopiracy as merely a slight systematic oversight 
that allowed for “bad” patents to be issued: 
 
This indigenous knowledge and use consists of "prior art". No patent 
should be given where prior art exists since patents are supposed to be 
granted only for new inventions on the basis of novelty and non-
obviousness. These criteria establish inventiveness, and patents are 
exclusive rights granted for inventions. […] If there were only one or 
two cases of such false claims to invention on the basis of Biopiracy, 
they could be called an error. However, Biopiracy is an epidemic. […] 
The problem is not, as was made out to be in the case of turmeric, an 
error made by a patent clerk. The problem is deep and systemic. And it 
calls for a systemic change, not a case by case challenge. 
 
If a patent system which is supposed to reward inventiveness and creativity 
systematically rewards piracy, if a patent system fails to honestly apply criteria of 
novelty and non-obviousness in the granting of patents related to indigenous 
knowledge, then the system is flawed, and it needs to change. It cannot be the basis of 
granting patents or establishing exclusive marketing rights. The problem of Biopiracy 
is a result of western style IPR systems, not the absence of such IPR systems in 
India.45 
 
Recalling the argument from the previous section that suggests that it is the movement 
of these contested objects out of the realm of nature into a separate realm of culture 
which makes them patentable, the claim here is that there is also too much culture, 
albeit rendered invisible and unrecognized, in these inventions for them to count as 
sufficiently inventive enough to be patentable. 
 
In many ways, this can also be seen to be an issue about what is allowed to count as a 
sufficient means through which to make the requisite movement from the natural to 
the knowledge-based. It is clear that in the dominant paradigm, which suggests that 
cases of biopiracy are simply “bad patents”, the biosciences are seen to be sufficient 
enough interlocutors to facilitate this transition. If one can demonstrate that the 
specific product of nature which enables their invention has been sufficiently removed 
from nature - for instance, a particular gene sequence has been isolated and purified - 
then the invention is rendered patentable. However, in many of the cases where 
biopiracy is being alleged, there is a question as to whether TK is able to count as 
fulfilling a similar function. In the last sentence of the passage quoted above, Shiva 
strikes out at this deficit model of IPR protection, which suggests that biopiracy only 
occurs where the IPR system is not evolved or robust enough to provide sufficient 
protection. Here, she links this claim with a critique of the IPR system itself, 
suggesting that the IPR system is, in fact, instrumental in causing biopiracy. The point 
where biopiracy interjects here is in claiming that TK is either invisible to the system, 
or is wilfully ignored by it. In these cases, if TK were recognized as a suitable enough 
interlocutor to make this nature-to-culture movement, then the claimed inventions 
would not be able to demonstrate that they have moved their invention far enough out 
of culture so as to make it patentable. Put another way, if TK were recognized as a 
suitable enough way to intervene on “products of nature” so as to make them useful 
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for humans, then the inventions or discovery projects that are alleged to be engaged in 
biopiracy would already be part of the public domain, and hence unpatentable. 
 
One of the most confusing aspects of the biopiracy discourse has been the issue of 
what is to be done to address the relationship between TK and the IPR system. If the 
“too cultural” critique were understood as being solely about a claim for reparations, 
or about laying the groundwork for the future profitability of TK as it appears to be 
for many who have used the term46, then it would not move the debate too far from 
merely adjusting the parameters of the IPR system to include TK in some way. For 
many of the biopiracy activists, simply adjusting the IPR system to include TK would 
be an incomplete version of biopiracy. For them, advocating this position side-by-side 
with one which suggests that the system itself is fatally flawed in its treatment of 
living things is unproblematic. It would be misleading, however, to attempt to portray 
this as a way in which “biopiracy” as a whole has betrayed itself. Conversely, the 
wide take-up of the term is a reminder that, once deployed into the charged 
atmosphere around IPR and biotechnology, these terms are constantly in flux and 
come to mean different things to different actors across the spectrum. 
 
This is also further evidenced in how the terms have been used by developing world 
governments, who have widely used the term biopiracy in some of their submissions 
to international forums such as the WTO and the CBD(c.f. Peru’s explanation of its 
National Anti-Biopiracy Commission47). Many of these submissions focus on 
developing some system for a “declaration of origin” for genetic material, with the 
idea being that the benefits from the exploitation of genetic resources would flow 
back to those countries from where the material “originated”. Of course, this does not 
converge with many of the biopiracy activists, who suggest that IPR-based systems of 
ownership are themselves largely at fault for biopiracy48. Again, the way in which the 
term itself has shown an ability to lend itself to related but quite different applications, 




This paper has demonstrated how projects like those gathered under the rubric of the 
bioeconomy rely on the creation and structuring of certain categories, such as genetic 
resources, for their functioning. It further demonstrated how the categories of nature 
and of invention are vital to the bioeconomy, and to the IPR system which forms an 
integral part to it. The paper then proceeded to analyse how the discourse(s) of 
biopiracy presents a challenge to the categories which underwrite the bioeconomy, 
and ultimately present a challenge to this kind of project. 
 
Even in the most rigorous and conventional understandings of IPR, were it 
demonstrated that an invention were either too natural (ie, was found in nature, as 
such) or too cultural (ie, was already known or was obvious) then it would be 
unpatentable. This paper has demonstrated that what sets biopiracy apart and gives it 
its rhetorical and conceptual force, however, is the conflation of these two, or, rather, 
their re-combination. The conflation of these two tenets of argument (too natural/too 
cultural) into one single semantic point – biopiracy – demonstrates the ways in which 
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a cascade of ethical questions can be combined in the complicated and ambivalent 
world of IPR and the biosciences. 
 
This paper has also helped to shed some light on how the natural and the cultural are 
represented in contemporary configurations of IPR and bioscience, notably at the 
point where these intersect with TK. Examples such as those instances alleged as 
biopiracy demonstrate how these objects, and their “in-between” positioning, 
confound the logic of IPR which makes up many of these economic future-making 
projects. Ultimately, a controversy like biopiracy brings nature and culture back 
together, and in so doing presents a challenge to the IPR system’s contention that they 
can be disentangled via patents. 
 
In effect, these activists are taking issue with what they see as a denial of both a 
system of knowledge (ie, traditional knowledge) and a system of nature (one in which 
patents on “products of nature” are considerably more limited than at present). 
Biopiracy challenges these aspects of the IPR system by presenting examples of 
things that are at once both in nature and in the public domain, and are not so easily 
abstracted from either of those realms when taken individually, or more crucially, 
when taken together. As developments in bioscience and biotechnology continue to 
shape and be shaped by concepts and processes such as the bioeconomy, there will 
undoubtedly be further examples of artefacts that are not so easily understood as 
invented, on one hand, or ownable on the other – something which should figure in 
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